Evidence map›Paper›PMID 27721835›Full record

ReviewStem cells international2016

Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence.

Anna Julie Peired, Alessandro Sisti, Paola Romagnani

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cells international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03939741 (Evaluation of Therapeutic Potential of Stromal Vascular Fraction), which is not on this map. Cited by 97 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 2 pooled it
16.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03939741 phase1 / phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Evaluation of Therapeutic Potential of Stromal Vascular Fraction (Autologous Adipose Derived Mesenchymal Stem Cell) Based Treatment for Chronic Kidney Disease

TypeinterventionalSponsorBangladesh Laser & Cell Surgery Institute & HospitalRan2019 to 2025Enrolled31ConditionsChronic Kidney DiseasesArmsSVF Containg Autologous Non Expanded ADSC
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 2 syntheses or guidelines pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Anna Julie PeiredExcellence Centre for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), Florence, Italy; Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.ORCID 0000-0001-9732-1369
Alessandro SistiExcellence Centre for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), Florence, Italy; Nephrology Unit, Meyer Children's University Hospital, Florence, Italy.ORCID 0000-0002-0099-4944
Paola RomagnaniExcellence Centre for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), Florence, Italy; Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy; Nephrology Unit, Meyer Children's University Hospital, Florence, Italy.ORCID 0000-0002-1774-8088
Temple Street Children's University Hospital · IEUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells form a population of self-renewing, multipotent cells that can be isolated from several tissues. Multiple preclinical studies have demonstrated that the administration of exogenous MSC could prevent renal injury and could promote renal recovery through a series of complex mechanisms, in particular via immunomodulation of the immune system and release of paracrine factors and microvesicles. Due to their therapeutic potentials, MSC are being evaluated as a possible player in treatment of human kidney disease, and an increasing number of clinical trials to assess the safety, feasibility, and efficacy of MSC-based therapy in various kidney diseases have been proposed. In the present review, we will summarize the current knowledge on MSC infusion to treat acute kidney injury, chronic kidney disease, diabetic nephropathy, focal segmental glomerulosclerosis, systemic lupus erythematosus, and kidney transplantation. The data obtained from these clinical trials will provide further insight into safety, feasibility, and efficacy of MSC-based therapy in renal pathologies and allow the design of consensus protocol for clinical purpose.

Identifiers

PMID27721835
PMCPMC5046016
OpenAlexW2522745591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.